CLINICAL TRIALS
WHAT IS A CLINICAL TRIAL?
A clinical trial is a type of research study that aims to explore whether a medical treatment is safe and effective for humans.
DO YOU NEED A CLINICAL TRIAL?
If you have liposarcoma progression despite the use of standard therapies and surgery, you or your doctor may want to investigate a clinical trial as an option for your treatment plan. While clinical trials are technically considered research, many liposarcoma patients have benefited from participation. Each clinical trial is designed for a specific purpose or condition.
WHAT ARE THE BENEFITS?
- The option of gaining access to new treatments after standard therapy fails.
- The opportunity to be the first to benefit from a new method under study.
- Receiving treatment at a major liposarcoma trial center.
- Close monitoring, advice, care, and support by a research team who has a better understanding of your disease or condition.
- The chance of helping future liposarcoma patients by contributing to medical research.
WHAT ARE THE RISKS?
- The new drug may not work for you.
- There may be unpleasant side effects as a response to the experimental treatment.
- Additional testing, time, and travel may be required.
- Some costs may not be covered by insurance companies.
CURRENT CLINICAL TRIALS:
CLINICAL TRIALS – UNITED STATES (RECRUITING):
- Sponsor: Lamassu Bio Inc
- Locations: Ohio: Gabrail Cancer Center, Canton, Ohio, 44718, United States; University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States; Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, 44195, United States
- Status: RECRUITING
- Phase: 1/2
- Conditions: Liposarcoma, Dedifferentiated Liposarcoma, MDM2 inhibitor
- Intervention/Treatment: Drug: SA53-OS
- Brief Summary: This study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06578624
- Sponsor: STORM Therapeutics LTD
- Locations: California: University of California, San Francisco, California, 94158 United States; Massachusetts: Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States; Michigan: START Midwest, Grand Rapids, Michigan, 49546, United States; New York: Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States; Northwell Health Cancer Institute Lake Success, New York, 11042, United States; Ohio: Case Western Reserve University, Cleveland, OH, 44106, United States; Texas: MD Anderson Cancer Center, Houston, Texas, 77030, United States; NEXT Oncology, Houston, Texas, 77054 United States; NEXT Oncology, Irving, Texas, 75039, United States; NEXT Oncology, San Antonio, Texas, 78229, United States; The START Center, San Antonio, Texas, 78229, United States; Virginia: NEXT Oncology, Fairfax, Virginia, 22031, United States; Washington: Fred Hutchinson Cancer Center, Seattle, Washington, 98109, United States
- Status: RECRUITING
- Phase: 1/2
- Conditions: Dedifferentiated Liposarcoma
- Intervention/Treatment: Combination Product: STC-15 in combination with toripalimab Drug: STC-15 monotherapy
- Brief Summary: This study is evaluating STC-15, an oral METTL3 inhibitor, in patients with advanced or metastatic cancers. The Phase 2 monotherapy portion includes patients with relapsed dedifferentiated liposarcoma (DDLPS) and leiomyosarcoma to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of STC-15…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06975293
- Sponsor: M.D. Anderson Cancer Center
- Locations: Texas: The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, United States
- Status: RECRUITING
- Phase: 2
- Conditions: De-differentiated/pleomorphic liposarcoma (DDLPS)
- Intervention/Treatment: Drug: Atezolizumab; Doxorubicin Hydrochloride
- Brief Summary: This clinical trial is studying whether a combination of chemotherapy, immunotherapy, radiation, and surgery can help delay or prevent the return of high-risk soft tissue sarcomas that can be surgically removed. Researchers are also evaluating the safety of this treatment approach and how tumors respond to therapy before and after surgery. For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT07049848
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
- Sponsor: Washington University School of Medicine
- Locations: Missouri: Washington University School of Medicine, St. Louis, Missouri, 63110, United States
- Status: RECRUITING
- Phase: 1
- Conditions: Advanced Liposarcoma
- Intervention/Treatment: Drug: Zanzalintinib; Eribulin
- Brief Summary: This study is testing the safety and optimal dosing of combining zanzalintinib with eribulin in patients with advanced liposarcoma or leiomyosarcoma who have received prior treatment. The study also explores whether this combination may improve progression-free survival compared to eribulin alone based on historical data.
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06957431
- Sponsor: Baylor College of Medicine
- Locations: Texas: Houston Methodist Hospital, Houston, Texas, 77030, United States
- Status: RECRUITING
- Phase: 1
- Conditions: Liposarcoma
- Intervention/Treatment: Genetic: 21.15.GPC3-CAR T cells
- Brief Summary: This research study combines two different ways of fighting cancer: antibodies and T cells. This Phase 1 trial is evaluating the safety and early effectiveness of a novel CAR T-cell therapy engineered to target GPC3-positive solid tumors, enhanced with IL-15 and IL-21 to improve persistence and tumor-killing ability. It uses a dose-escalation design in adults with relapsed or refractory disease to determine a safe dose and assess preliminary anti-tumor response.
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06198296
- Sponsor: Memorial Sloan Kettering Cancer Center
- Locations: New York: Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States; Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States
- Status: RECRUITING
- Phase: 1
- Conditions: Uveal Melanoma; Melanoma; Metastatic Uveal Melanoma; Metastatic Melanoma; Dedifferentiated Liposarcoma
- Intervention/Treatment: Biological: Lifileucel (LN-144/LN-145)
- Brief Summary: This study is a Phase 1 trial testing lifileucel (TIL therapy), a personalized immunotherapy made from a patient’s own immune cells. It includes adults with advanced cancers such as dedifferentiated liposarcoma after prior treatment. Patients have a tumor sample collected, followed by a one-time cell infusion and immune support therapy.
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05607095
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
- Sponsor: M.D. Anderson Cancer Center
- Locations: Texas: MD Anderson Cancer Center, Houston, Texas, 77030, United States
- Status: RECRUITING
- Phase: 1
- Conditions: Synovial Sarcoma; Myxoid/Round Cell Liposarcoma
- Intervention/Treatment: Drug: Fludarabine phosphate; NY-ESO-1 TCR/IL-15 NK; Cyclophosphamide
- Brief Summary: The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06083883
- Sponsor: Baylor College of Medicine
- Locations: Texas: Texas Children’s Hospital, Houston, Texas, 77030, United States
- Status: RECRUITING
- Phase: 1
- Conditions: Liver Cancer; Rhabdomyosarcoma; Malignant Rhabdoid Tumor; Liposarcoma; Wilms Tumor; Yolk Sac Tumor
- Intervention/Treatment: Genetic: CARE T cells; Drug: Cytoxan; Fludara
- Brief Summary: Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CARE T cells, a new experimental treatment …
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04715191
- Sponsor: National Cancer Institute (NCI)
- Locations: California: Los Angeles General Medical Center, Los Angeles, California, 90033, United States; USC / Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States; Colorado: UCHealth University of Colorado Hospital, Aurora, Colorado, 80045, United States; Florida: (SUSPENDED) University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, 33136, United States; Illinois: University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States; UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, 60451, United States; University of Chicago Medicine-Orland Park, Orland Park, Illinois, 60462, United States; Maryland: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, 21287, United States; National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, 20892, United States; Massachusetts: Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States; Michigan: (SUSPENDED) University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States ; Missouri: Washington University School of Medicine, St Louis, Missouri, 63110, United States; Siteman Cancer Center-South County, St Louis, Missouri, 63129, United States; Pennsylvania: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States; Texas: UT MD Anderson Cancer Center, Houston, Texas, 77030, United States; Virginia: University of Virginia Cancer Center, Charlottesville, Virginia, 22908, United States
- Status: RECRUITING
- Phase: 1
- Conditions: Metastatic Dedifferentiated Liposarcoma; Metastatic Leiomyosarcoma; Metastatic Myxofibrosarcoma; Metastatic Sarcoma; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Unresectable Dedifferentiated Liposarcoma; Unresectable Leiomyosarcoma; Unresectable Myxofibrosarcoma; Unresectable Sarcoma; Unresectable Synovial Sarcoma; Unresectable Undifferentiated Pleomorphic Sarcoma
- Intervention/Treatment: Procedure: Biopsy; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Drug: Pegylated Liposomal Doxorubicin Hydrochloride; Peposertib
- Brief Summary: This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced)…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05711615
- Sponsor: National Cancer Institute (NCI)
- Locations: MD Anderson Cancer Center, Houston, Texas, 77030, United States
- Status: RECRUITING
- Phase: 1/2
- Conditions: Dedifferentiated Liposarcoma
- Intervention/Treatment: Drug: Abemaciclib; Procedure: Biopsy; Biospecimen Collection; Computed Tomography; Drug: Docetaxel; GemcitabineBTX-A51
- Brief Summary: This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usual treatment of gemcitabine with docetaxel for the treatment of patients with soft tissue sarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) (phase 1) or patients with dedifferentiated liposarcoma (phase 2).
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06498648
- Sponsor: St. Jude Children’s Research Hospital
- Locations: Georgia: Children’s Healthcare of Atlanta, Atlanta, Georgia, 30329, United States; Illinois: Lurie Children’s Hospital of Chicago, Chicago, Illinois, 60611, United States; Louisiana: Our Lady of the Lake Children’s Hospital, Baton Rouge, Louisiana, 70809, United States; Massachusetts: Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States; Missouri: Washington University Medical Center, St Louis, Missouri, 63110, United States; Ohio: Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, 45229, United States; Tennessee: St. Jude Children’s Research Hospital, Memphis, Tennessee, 38105, United States
- Status: RECRUITING
- Phase: 1/2
- Conditions: Non-rhabdomyosarcoma; Adipocytic Neoplasm; Liposarcoma
- Intervention/Treatment: Procedure: Surgical resection; Radiation: Proton beam radiation therapy; Drug: Pazopanib; Ifosfamide; Doxorubicin; Selinexor
- Brief Summary: The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS)…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06239272
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
- Sponsor: Memorial Sloan Kettering Cancer Center
- Locations: New Jersey: Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, 07920, United States; Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States; Memorial Sloan Kettering Bergen, Montvale, 07645, New Jersey, United States; New York: Memorial Sloan Kettering Cancer Center Suffolk- Commack, Commack, New York, 11725, United States; Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States; Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States; Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States
- Status: RECRUITING
- Phase: 1/2
- Conditions: Well Differentiated Liposarcoma; Dedifferentiated Liposarcoma: Liposarcoma: Myxoid Liposarcoma; Round Cell Liposarcoma: Myxoid Pleomorphic Liposarcoma; Pleomorphic Liposarcoma; Unresectable Liposarcoma; Unresectable Dedifferentiated Liposarcoma; Unresectable Well Differentiated Liposarcoma
- Intervention/Treatment: Drug: Mirdametinib; Palbociclib
- Brief Summary: The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06843967
- Sponsor: QBiotics Group Limited
- Locations: New York: Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States
- Status: RECRUITING
- Phase: 2
- Conditions: Soft Tissue Sarcoma
- Intervention/Treatment: Drug: Tigilanol Tiglate
- Brief Summary: This study is an open-label, single-arm study is evaluating the preliminary efficacy and safety of intratumoral tigilanol tiglate in adults with advanced or metastatic soft tissue sarcoma of the extremities or body wall. The trial focuses on tumor ablation and overall disease control, while also assessing safety, pharmacokinetics, and potential immune responses.
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05755113
Genomic Risk in Retroperitoneal Sarcoma
- Sponsor: Fox Chase Cancer Center
- Location: Pennsylvania: Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States
- Status: RECRUITING
- Phase: Not Applicable
- Conditions: Retroperitoneal Liposarcoma; Soft Tissue Sarcoma
- Intervention/Treatment: Other: Biospecimen sample collection during standard-of-care surgery
- Brief Summary: The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease…
More information and eligibility requirements can be found here: STUDY: NCT06436846
CLINICAL TRIALS – UNITED STATES & INTERNATIONAL (RECRUITING):
Actinium Therapy for Late-stage Aggressive Sarcomas (ATLAS)
- Sponsor: Ratio Therapeutics, Inc.
- Locations: United States– California: UCLA, Los Angeles, California, 90095, United States; Minnesota: Mayo Clinic, Rochester, Minnesota, 55905, United States; New York: Memorial Sloane Kettering Cancer Center, New York, New York, 10065, United States; Ohio: Case Western, Cleveland, Ohio, 44106, United States; Texas: MD Anderson Cancer Center, Houston, 77230, Texas, United States; Canada: Princess Margaret Cancer Centre, Toronto, Ontario, Canada, M5G 2M9
- Status: RECRUITING
- Phase: 1/2
- Conditions: Advanced Soft Tissue Sarcoma
- Intervention/Treatment: Drug: [Ac 225]RTX-2358 Diagnostic Test: [Cu64]LNTH-1363S
- Brief Summary: The RTX-2358-101 trial is a Phase 1/2 study evaluating the safety, tolerability, appropriate dose, and potential effectiveness of the radiopharmaceutical [Ac225]RTX-2358 in adults with relapsed or treatment-resistant soft tissue sarcoma. For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT07156565
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism (Tumor HI)
- Sponsor: Rezolute
- Locations: United States, France, Netherlands, Switzerland & United Kingdom (See link for various location options.)
- Status: RECRUITING
- Phase: 3
- Conditions: Liposarcoma
- Intervention/Treatment: Drug: Ersodetug
- Brief Summary: This Phase 3 study is evaluating the safety and effectiveness of ersodetug, given alongside standard treatments, in patients with severe low blood sugar (hypoglycemia) caused by insulin- or IGF-producing tumors that cannot be surgically removed or adequately controlled with current therapies. About 16 participants across multiple countries will receive weekly ersodetug treatments for 8 weeks, with researchers monitoring blood sugar control, side effects, and overall tolerability. For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06881992
- Sponsor: Australia and New Zealand Sarcoma Association
- Locations: United States, Australia, Belgium, Brazil, Canada, France, Netherlands & Poland (See link for various location options.)
- Status: RECRUITING
- Phase: n/a
- Conditions: Retroperitoneal Liposarcoma; Well-differentiated and/or dedifferentiated liposarcoma
- Intervention/Treatment:
- Brief Summary: This study is tracking treatment outcomes in patients with recurrent, localized retroperitoneal well-differentiated or dedifferentiated liposarcoma that can be removed with surgery. Researchers will collect long-term data on treatments, survival, complications, and quality of life over 5 years to help validate a tool used to predict outcomes and guide future care decisions. For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT07377747
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- Sponsor: Avacta Life Sciences Ltd
- Locations: United States & United Kingdom (See link for various location options.)
- Status: RECRUITING
- Phase: 1
- Conditions: Salivary Gland Tumor; Urothelial Carcinoma; Ovarian Carcinoma; Breast Cancer; Soft Tissue Sarcoma
- Intervention/Treatment: Drug: AVA6000
- Brief Summary: This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04969835
- Sponsor: BeOne Medicines
- Locations: United States, Australia, Brazil, China, France, Japan, Malaysia, Moldova, New Zealand, South Korea, & Thailand (See link for various location options.)
- Status: RECRUITING
- Phase: 1
- Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer
- Intervention/Treatment: Drug: BGB-43395, Fulvestrant, Letrozole, Elacestrant
- Brief Summary: This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06120283
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Sponsor: Milton S. Hershey Medical Center
- Locations: United States & Canada (See link for various location options.)
- Status: RECRUITING
- Phase: 1/2
- Conditions: Neuroblastoma Recurrent; Ewing’s Sarcoma Recurrent; Osteosarcoma Recurrent; Rhabdomyosarcoma Recurrent; Liposarcoma Recurrent
- Intervention/Treatment: Drug: Silmitasertib; Irinotecan; Temozolomide; Vincristine
- Brief Summary: The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06541262
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma (ADCElerate1)
- Sponsor: Adcendo ApS
- Locations: United States, Belgium, France, Germany & United Kingdom (See link for various location options.)
- Status: RECRUITING
- Phase: 1/2
- Conditions: Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
- Intervention/Treatment: Biological: Antibody-drug conjugate (ADC)
- Brief Summary: The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06797999
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (STRASS2)
- Sponsor: European Organisation for Research and Treatment of Cancer – EORTC
- Locations: United States, Australia, Canada, Cyprus, Czechia, Denmark, France, Germany, Italy, Japan, Netherlands, Poland, Slovakia, Spain & United Kingdom (See link for various location options.)
- Status: RECRUITING
- Phase: 3
- Conditions: Retroperitoneal Sarcoma; Liposarcoma; Leiomyosarcoma
- Intervention/Treatment: Procedure: Surgery; Drug: Preoperative chemotherapy
- Brief Summary: This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04031677
- Sponsor: National Cancer Institute (NCI)
- Locations: United States, Canada, & Puerto Rico (See link for various location options.)
- Status: RECRUITING
- Phase: 3
- Conditions: Dedifferentiated Liposarcoma
- Intervention/Treatment: Procedure: Biospecimen Collection; Diagnostic Imaging Testing; Drug: Doxorubicin; Procedure: Echocardiography Test; Multigated Acquisition Scan; Biological: Pembrolizumab
- Brief Summary: This trial evaluates whether adding the immunotherapy pembrolizumab to standard doxorubicin chemotherapy improves outcomes compared to doxorubicin alone in patients with metastatic or unresectable dedifferentiated liposarcoma, undifferentiated pleomorphic sarcoma, and related poorly differentiated sarcomas. The study primarily measures progression-free survival and overall survival to determine if the combination approach provides a clinical benefit. For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06422806
CLINICAL TRIALS – INTERNATIONAL (RECRUITING):
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS)
- Sponsor: Grupo Espanol de Investigacion en Sarcomas
- Locations: France, Italy & Spain (See link for various location options.)
- Status: RECRUITING
- Phase: 1/2
- Conditions: Liposarcoma, Myxoid; Sarcoma, Soft Tissue; Leiomyosarcoma; Liposarcoma; Pleomorphic Liposarcoma
- Intervention/Treatment: Drug: Trabectedin; Radiation: Radiotherapy
- Brief Summary: Phase I-II trial that combines trabectedin plus radiotherapy for tumor reduction response measure in four cohorts of patients…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT02275286
- Sponsor: Ascentage Pharma Group Inc.
- Locations: China: Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, Zhejiang, 310005, China; Shanghai East Hospital (East Hospital affiliated to Tongji University), Shanghai, China
- Status: RECRUITING
- Phase: 1/2
- Conditions: Liposarcoma; Advanced Solid Tumor
- Intervention/Treatment: Drug: APG-115; Toripalimab
- Brief Summary: Part 1 is a phase Ib standard “3 + 3” design, will be employed to determine the MTD of APG-115 by assessing the DLT of APG-115 in combination with PD-1 inhibitor(toripalimab) in advanced solid tumors. Part 2 is a Simon two-stage phase II study design. At RP2D of APG-115 in combination with toripalimab in advanced liposarcoma, approximately 34 patients will be treated with the combination until disease progression, unacceptable toxicity, or another discontinuation criterion is met…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04785196
- Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
- Locations: CHINA (See link for various location options.)
- Status: RECRUITING
- Phase: 1/2
- Conditions: Advanced Solid Tumors
- Intervention/Treatment: Drug: SPH4336; Cadonilimab
- Brief Summary: This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05944224
- Sponsor: Lund University Hospital
- Locations: Norway: Oslo University Hospital HF, Oslo, Norway; Sweden: Sahlgrenska University Hospital, Göteborg, Sweden; Skane University Hospital, Lund, Sweden; Karolinska University Hospital, Stockholm, Sweden
- Status: RECRUITING
- Phase: 2
- Conditions: Dedifferentiated Liposarcoma
- Intervention/Treatment: Drug: Pemigatinib; Retifanlimab
- Brief Summary: Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06389799
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas (ESPACE)
- Sponsor: Institut du Cancer de Montpellier – Val d’Aurelle
- Locations: France: Institut du Cancer de Montpellier – Val d’Aurelle, Montpellier, 34298, France
- Status: RECRUITING
- Phase: Not Applicable
- Conditions: Liposarcoma, Atypical Lipomatous Tumor
- Intervention/Treatment: Diagnostic Test: Blood sampling
- Brief Summary: The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH…
More information and eligibility requirements can be found here: STUDY: NCT04224064
International Prospective Registry on Local Treatment Approaches in MLS
- Sponsor: The Netherlands Cancer Institute
- Locations: Netherlands: The Netherlands Cancer Institute, Amsterdam, 1066CX, Netherlands
- Status: RECRUITING
- Phase: Not Applicable
- Conditions: Liposarcoma, Myxoid Liposarcoma
- Intervention/Treatment: Procedure: Surgery; Radiation: Preoperative RT 36Gy; Preoperative RT 50Gy; Postoperative RT 50-66Gy; RT 36Gy
- Brief Summary: To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04699292
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
- Sponsor: Valo Therapeutics Oy
- Locations: Germany: (Active, Not Recruiting) Krankenhaus Nordwest, Frankfurt, Germany; (Completed) National Center for Tumor Diseases, Heidelberg, Germany; (Completed) Universitatsklinikum Tubingen, Tubingen, Germany; Italy: Istituto di Candiolo Fondazione del Piemonte per l’oncologia IRCCS, Candiolo, Italy
- Status: RECRUITING
- Conditions: Melanoma (Skin); Triple-Negative Breast Cancer; Non-Small Cell Lung Cancer; Synovial Sarcoma; Myxoid Liposarcoma; Colorectal Cancer
- Intervention/Treatment: Biological: PeptiCRAd-1; Drug: Cyclophosphamide; Pembrolizumab
- Brief Summary: This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05492682
CLINICAL TRIALS – (NOT YET RECRUITING):
- Sponsor: Iovance Biotherapeutics, Inc.
- Locations:
- Status: NOT YET RECRUITING
- Phase: 2
- Conditions: De-differentiated Liposarcoma (DDLPS)
- Intervention/Treatment: Biological: Lifileucel
- Brief Summary: The SARATOGA study is evaluating the safety and effectiveness of lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy, in adults with previously treated advanced soft tissue sarcoma. For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT07741877
CLINICAL TRIALS – (ACTIVE, NOT RECRUITING):
SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma
- Sponsor: Sarcoma Alliance for Research through Collaboration
- Locations: Colorado: University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, 80045, United States; Florida: Mayo Clinic Florida, Jacksonville, Florida, 32224, United States; Illinois: Northwestern University, Chicago, Illinois, 60611, United States; Massachusetts: Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States; Missouri: Washington University School of Medicine, Saint Louis, Missouri, 63129, United States; New York: Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States; North Carolina: Duke University, Durham, North Carolina, 27710, United States; Oregon: Oregon Health & Science University, Portland, Oregon, 97239, United States; Washington: University of Washington, Seattle, Washington, 98109, United States
- Status: ACTIVE, NOT RECRUITING
- Phase: 3
- Conditions: Advanced Dedifferentiated Liposarcoma
- Intervention/Treatment: Drug: Abemaciclib; Placebo
- Brief Summary: This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with progression of disease will cross over to open label abemaciclib… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04967521
- Sponsor: Boehringer Ingelheim
- Locations: United States, Argentina, Australia, Belgium, Canada, China, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Norway, Poland, Spain, Sweden, Taiwan & United Kingdom (See link for various location options.)
- Status: ACTIVE, NOT RECRUITING
- Phase: 2
- Conditions: Solid Tumor
- Intervention/Treatment: Drug: Brigimadlin
- Brief Summary: This study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a MDM2 inhibitor that was being developed to treat cancer.
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06619509
BTX-A51 in Patients with Liposarcoma or CIC-rearranged Sarcoma
- Sponsor: Michael Wagner, MD
- Locations: Massachusetts: Brigham and Women’s Hospital, Boston, Massachusetts, 02215, United States; Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States
- Status: ACTIVE, NOT RECRUITING
- Phase: 1
- Conditions: Liposarcoma, Recurrent Liposarcoma, Metastatic Liposarcoma, Unresectable Liposarcoma, MDM2 Gene Amplification
- Intervention/Treatment: Drug: BTX-A51
- Brief Summary: This study is testing if the recommended dose of BTX-A51 is safe and tolerable in participants with liposarcoma…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06414434
- Sponsor: Pfizer
- Locations: United States, Argentina, China, Czechia, Japan, Mexico, Slovakia & United Kingdom (See link for various location options.)
- Status: ACTIVE, NOT RECRUITING
- Phase: 2
- Conditions: Liposarcoma; Prostate Cancer; Breast Neoplasms; Adenocarcinoma of Lung
- Intervention/Treatment: Drug: PF-07220060; Combination Product: Letrozole; Fulvestrant; Drug: Midazolam; Combination Product: Enzalutamide
- Brief Summary: This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04557449
- Sponsor: Baylor College of Medicine
- Locations: Texas: Texas Children’s Hospital, Houston, Texas, 77030, United States
- Status: ACTIVE, NOT RECRUITING
- Phase: 1
- Conditions: Liver Cancer; Rhabdomyosarcoma; Malignant Rhabdoid Tumor; Liposarcoma; Wilms Tumor; Yolk Sac Tumor
- Intervention/Treatment: Genetic: AGAR T cells
- Brief Summary: Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called AGAR T cells, a new experimental treatment…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04377932
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1)
- Sponsor: Sotio Biotech Inc.
- Locations: United States & United Kingdom (See link for various location options.)
- Status: ACTIVE, NOT RECRUITING
- Phase: 1/2
- Conditions: Hepatocellular Carcinoma; Squamous Cell Carcinoma of the Lung; Merkel Cell Carcinoma; Myxoid/Round Cell Liposarcoma
- Intervention/Treatment: Biological: CAR-GPC3 T Cells
- Brief Summary: This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05120271
- Sponsor: Baylor College of Medicine
- Locations: Texas: Houston Methodist Hospital, Houston, Texas, 77030, United States
- Status: ACTIVE, NOT RECRUITING
- Phase: 1
- Conditions: Liver Cell Carcinoma; Solid Tumor; Wilms Tumor; Malignant Rhabdoid Tumor; Yolk Sac Tumor; Rhabdomyosarcoma; Liposarcoma; Embryonal Sarcoma of the Liver
- Intervention/Treatment: Genetic: CATCH T cells
- Brief Summary: Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CATCH T cells, a new experimental treatment…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05103631
- Sponsor: National Cancer Institute LAO
- Locations: United States & Canada (See link for various location options.)
- Status: ACTIVE, NOT RECRUITING
- Phase: 2
- Conditions: Locally Advanced Extraskeletal Myxoid Chondrosarcoma; Locally Advanced Leiomyosarcoma; Locally Advanced Liposarcoma; Locally Advanced Undifferentiated Pleomorphic Sarcoma; Locally Advanced Unresectable Soft Tissue Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma
- Intervention/Treatment: Procedure: Biopsy; Biospecimen Collection; Drug: Cabozantinib; Procedure: Computed Tomography; Biological: Ipilimumab; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab
- Brief Summary: This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05836571
- Sponsor: Boundless Bio, Inc.
- Locations: United States (See link for various location options.)
- Status: ACTIVE, NOT RECRUITING
- Conditions: Non-small Cell Lung Cancer; Non-Small Cell Lung Adenocarcinoma; Non-Small Cell Squamous Lung Cancer; Head and Neck Squamous Cell Carcinoma; Esophageal Cancer; Gastric Cancer; Breast Cancer; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Liposarcoma
- Intervention/Treatment: Drug: BBI-355; Erlotinib; Futibatinib
- Brief Summary: BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05827614
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
- Sponsor: Memorial Sloan Kettering Cancer Center
- Locations: New Jersey: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, 07920, United States; Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, 07748, United States; Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, 07645, United States; New York: Memorial Sloan Kettering Suffolk – Commack (Limited Protocol Activities), Commack, New York, 11725, United States; Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, 10604, United States; Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States; Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, 11553, United States
- Status: ACTIVE, NOT RECRUITING
- Phase: 2
- Conditions: Dedifferentiated Liposarcoma; Soft Tissue Sarcoma; Sarcoma,Soft Tissue; Sarcoma; Recurrent Dedifferentiated Liposarcoma; Unresectable Dedifferentiated Liposarcoma; Metastatic Dedifferentiated Liposarcoma
- Intervention/Treatment: Drug: Etrumadenant; Zimberelimab
- Brief Summary: Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread beyond its original location (advanced)…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05886634
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
- Sponsor: USWM CT, LLC
- Locations: United States, Canada, France, Spain & United Kingdom (See link for various location options.)
- Status: ACTIVE, NOT RECRUITING
- Phase: 2
- Conditions: Synovial Sarcoma; Myxoid Liposarcoma
- Intervention/Treatment: Genetic: afamitresgene autoleucel (previously ADP-A2M4)
- Brief Summary: This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) …
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04044768
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa)
- Sponsor: M.D. Anderson Cancer Center
- Locations: Texas: MD Anderson Cancer Center, Houston, Texas, 77030, United States
- Status: ACTIVE, NOT RECRUITING
- Phase: 2
- Conditions: Metastatic Angiosarcoma; Metastatic Dedifferentiated Liposarcoma; Metastatic Osteosarcoma; Recurrent Angiosarcoma; Recurrent Dedifferentiated Liposarcoma; Recurrent Osteosarcoma; Refractory Dedifferentiated Liposarcoma; Refractory Osteosarcoma
- Intervention/Treatment: Biological: Durvalumab; Oleclumab
- Brief Summary: This phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to treatment (refractory) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as oleclumab and durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread…
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04668300
- Sponsor: Alliance for Clinical Trials in Oncology
- Locations: United States (See link for various location options.)
- Status: ACTIVE, NOT RECRUITING
- Conditions: Advanced Dedifferentiated Liposarcoma; Locally Advanced Dedifferentiated Liposarcoma; Metastatic Dedifferentiated Liposarcoma; Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Unresectable Dedifferentiated Liposarcoma
- Intervention/Treatment: Drug: Palbociclib; Biological: Cemiplimab; Procedure: Magnetic Resonance Imaging; Computed Tomography; Biospecimen collection; Other: Questionnaire Administration
- Brief Summary: This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) …
For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05694871
Updated 9/1/2026